Communiqués Neurocrine Biosciences, Inc.

Actions

NBIX

US64125C1099

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 17:22:15 08/05/2026			Varia. 5j.	Varia. 1 janv.
153,16 ^USD	+2,38 %		+16,05 %	+7,83 %

07/05	NEUROCRINE BIOSCIENCES, INC. : Deutsche Bank Securities confirme sa recommandation neutre	ZM
06/05	NEUROCRINE BIOSCIENCES, INC. : Opinion positive de Wedbush	ZM

Communiqués

06/05	Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia	PR
06/05	Neurocrine Biosciences : Presentation (NBIX Q1 2026 Earnings Presentation Final 0556)	PU
05/05	Neurocrine: Q1 Earnings Snapshot	AQ
05/05	Neurocrine Biosciences Reports First-Quarter 2026 Financial Results	PR
05/05	Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026	PR
04/05	Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment	PR
04/05	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist	PR
01/05	Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia	PR
29/04	Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale	PR
22/04	Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia	PR
15/04	Neurocrine Biosciences : 2026 Proxy Statement (NBIX 2026 Proxy Statement)	PU
15/04	Neurocrine Biosciences : 2025 Annual Report*	PU
14/04	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results	PR
14/04	Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR	PR
06/04	Neurocrine Biosciences : Presentation (FINAL NBIX SLNO Investor Presentation 0466 Final)	PU
06/04	Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio	PR
26/03	Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings	PR
24/03	Biocom Appoints New Members to Its Board of Directors	AQ
17/03	Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer	PR
10/03	Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum	PR
24/02	Neurocrine Biosciences to Present at Upcoming Investor Conferences in March	PR
12/02	Neurocrine Biosciences : Presentation (Final NBIX Q4 and FY 2025 Earnings Presentation 02 WT5vGfd16)	PU
11/02	Neurocrine Biosciences : Presentation (Final NBIX Q4 and FY 2025 Earnings Presentation 0216)	PU
11/02	Neurocrine: Q4 Earnings Snapshot	AQ
11/02	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026	PR